Skip to main content
Premium Trial:

Request an Annual Quote

Rheonix Gets FDA Emergency Use Authorization for Coronavirus MDx Test

NEW YORK – Rheonix said on Thursday that it has received Emergency Use Authorization from the US Food and Drug Administration for the Rheonix COVID-19 MDx assay.

The endpoint RT-PCR test is processed on the company's Encompass CARD cartridge, which runs on Rheonix's Encompass MDx workstation. It is intended for the qualitative detection of nucleic acid from SARS-CoV-2 in respiratory samples from individuals suspected by their healthcare provider of having COVID-19.

Rheonix said that the assay is fully automated and can provide same-day results for low- and medium-throughput laboratories. The company said that it has begun shipping the workstation and test kits to high-need local and regional hospital laboratories to enable them to begin testing immediately.

Ithaca, NY-based Rheonix is currently seeking full FDA clearance for the Encompass workstation and a triplex sexually transmitted infection assay to simultaneously detect nucleic acid from Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis from patient samples.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.